SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Huth who wrote (5)10/29/1998 12:50:00 PM
From: crysball  Read Replies (1) of 1386
 
Richard, your suggestion of reporting the prescription trend data of Lotemax and Alrex separately has merit, and will hopelfully be read by and acted upon by PARS when they write their Q3 release. .....as a positive trend would certaily help allay the fears of those looking at raw Q2 to Q3 numbers which only reflect filling the pipeline.

The high short level reported on the the other PARS SI thread may also be a reflection of anticipation by sellers who expect a drop from Q2 to Q3 as the pipeline is filled.

Since PARS has scheduled Investor conferences immediately following the release I suspect the data will not be very negative.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News